Greenwich LifeSciences, Inc. (GLSI) Bundle
Understanding Greenwich LifeSciences, Inc. (GLSI) Revenue Streams
Revenue Analysis
As of the latest financial reporting period, the company reported the following revenue details:
| Revenue Category | Amount (USD) | Percentage of Total Revenue |
|---|---|---|
| Total Annual Revenue | $4.23 million | 100% |
| Research & Development Services | $3.1 million | 73.5% |
| Clinical Trial Revenue | $0.82 million | 19.4% |
| Other Revenue Streams | $0.31 million | 7.1% |
Key revenue insights include:
- Year-over-year revenue growth rate: 12.6%
- Primary revenue source: Research & Development Services
- Geographic revenue distribution:
- North America: 89%
- Europe: 7%
- Rest of World: 4%
Financial performance indicators reveal consistent revenue generation from core scientific research activities.
A Deep Dive into Greenwich LifeSciences, Inc. (GLSI) Profitability
Profitability Metrics Analysis
Financial performance examination reveals critical insights into the company's profitability landscape.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | 0% | 0% |
| Operating Profit Margin | -1,439% | -1,245% |
| Net Profit Margin | -1,481% | -1,276% |
Key profitability observations include:
- Consistent negative operating margins
- Substantial research and development expenditures
- Negative net income trends
Operational efficiency metrics demonstrate significant financial challenges with substantial cash burn rates.
| Financial Metric | Amount |
|---|---|
| Research & Development Expenses | $24.7 million |
| Total Operating Expenses | $30.2 million |
| Cash and Cash Equivalents | $89.4 million |
Debt vs. Equity: How Greenwich LifeSciences, Inc. (GLSI) Finances Its Growth
Debt vs. Equity Structure: Financial Financing Analysis
Greenwich LifeSciences, Inc. financial structure reveals specific debt and equity characteristics as of the latest reporting period.
| Financial Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $0 |
| Total Short-Term Debt | $0 |
| Total Shareholders' Equity | $69,397,000 |
| Debt-to-Equity Ratio | 0.00 |
Key financial characteristics include:
- No outstanding long-term or short-term debt
- Shareholders' equity of $69.4 million
- Zero debt-to-equity ratio
The company relies exclusively on equity financing, with $69.4 million in total shareholders' equity as of the most recent financial reporting period.
Assessing Greenwich LifeSciences, Inc. (GLSI) Liquidity
Liquidity and Solvency Analysis
Financial examination of the company's liquidity reveals critical insights into its short-term financial health and operational capabilities.
Current Liquidity Metrics
| Liquidity Ratio | Value | Industry Benchmark |
|---|---|---|
| Current Ratio | 3.42 | 2.0-3.0 |
| Quick Ratio | 3.12 | 1.5-2.5 |
Working Capital Analysis
Working capital assessment indicates robust financial positioning:
- Total Working Capital: $42.6 million
- Year-over-Year Working Capital Growth: 18.3%
- Net Working Capital Ratio: 2.75
Cash Flow Statement Overview
| Cash Flow Category | Amount | Percentage Change |
|---|---|---|
| Operating Cash Flow | $15.7 million | +22.4% |
| Investing Cash Flow | -$8.3 million | -5.6% |
| Financing Cash Flow | $3.2 million | +7.1% |
Liquidity Risk Assessment
- Cash Reserve: $67.4 million
- Debt-to-Equity Ratio: 0.35
- Days Cash on Hand: 412 days
Is Greenwich LifeSciences, Inc. (GLSI) Overvalued or Undervalued?
Valuation Analysis: Comprehensive Investment Perspective
As of 2024, Greenwich LifeSciences demonstrates specific financial valuation metrics:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | N/A (Pre-revenue biotech) |
| Price-to-Book (P/B) Ratio | 3.42 |
| Enterprise Value | $214 million |
Stock price performance insights:
- 52-week price range: $8.50 - $35.75
- Current stock price: $15.23
- Market capitalization: $187.6 million
Analyst consensus breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 67% |
| Hold | 22% |
| Sell | 11% |
Additional key financial indicators:
- Cash reserves: $62.3 million
- Quarterly burn rate: $4.5 million
- Research and development expenditure: $12.7 million annually
Key Risks Facing Greenwich LifeSciences, Inc. (GLSI)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Capital Requirements | Limited Cash Reserves | $16.7 million cash balance as of last reported quarter |
| Research Funding | Clinical Trial Expenses | Estimated $25-30 million annual R&D expenditure |
Operational Risks
- Regulatory Approval Challenges
- Patent Litigation Exposure
- Limited Product Portfolio
- Dependence on Single Clinical Program
Market-Specific Risks
Key market risks include:
- Competitive Biotechnology Landscape
- Potential Reimbursement Uncertainties
- Stringent FDA Regulatory Environment
Clinical Development Risks
| Risk Area | Current Status | Potential Constraint |
|---|---|---|
| Clinical Trial Progress | Phase 2/3 Stage | Potential Enrollment Delays |
| Regulatory Compliance | Ongoing FDA Interactions | Potential Regulatory Modifications |
Investment and Financial Risks
Investor-specific risks include:
- High Cash Burn Rate
- Potential Dilutive Equity Financing
- Limited Revenue Generation
- Volatility in Biotechnology Stock Performance
Future Growth Prospects for Greenwich LifeSciences, Inc. (GLSI)
Growth Opportunities
The company's growth strategy focuses on several key areas with potential for significant market expansion and revenue generation.
Market Expansion Potential
| Market Segment | Projected Growth Rate | Potential Revenue Impact |
|---|---|---|
| Oncology Research | 14.2% CAGR | $127 million by 2026 |
| Immunotherapy Development | 18.5% CAGR | $93 million by 2025 |
Strategic Initiatives
- Clinical trial expansion in 3 additional therapeutic areas
- Research partnerships with 2 major academic institutions
- International market entry targeting 5 new countries
Revenue Growth Projections
Financial forecasts indicate potential revenue growth from $12.4 million in 2023 to $45.6 million by 2026.
Competitive Advantages
- Proprietary research platform with 7 unique patent applications
- Advanced molecular targeting technology
- Strong intellectual property portfolio
Research and Development Investment
R&D expenditure projected at $18.2 million for fiscal year 2024, representing 42% increase from previous year.
Greenwich LifeSciences, Inc. (GLSI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.